PCI for stable coronary disease [3]

New England Journal of Medicine

Volumn 357, Issue 4, 2007, Pages 415-416

  Shah, Atman P ^a   Shavelle, David M ^a   French, William J ^a  

^a HARBOR UCLA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CORONARY ARTERY DISEASE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INCIDENCE; LETTER; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RISK REDUCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; CARDIOVASCULAR DISEASE; DRUG ANTAGONISM; EPIDEMIOLOGY; NOTE; STENT;

FIBRINOGEN RECEPTOR;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR DISEASES; CORONARY DISEASE; HUMANS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; SELECTION BIAS; STENTS;

EID: 34547207211     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: None     Document Type: Letter

References (3)

1. Serruys PW, de Jaegere P, Kiemeneij F, et al. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994;331:489-95.
2. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation: a randomised, placebo-controlled trial. Lancet 2000;356:2037-44. [Erratum, Lancet 2001;357:1370.]
3. Tcheng JE, Kandzari DE, Grines CL, et al. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial. Circulation 2003;108:1316-23.